A 2026 FAERS pharmacovigilance study of 28,938 dystonia reports found the strongest reporting signal for metoclopramide, while antipsychotics dominated the high-volume psychiatric medication signal and most timed cases began within 30 days of drug exposure.1 Research Highlights 28,938 dystonia reports: Chen et al. analyzed 27,618 patients represented in FAERS reports from Q1 2004 through Q3 …
A 2026 Neurological Sciences brief communication added 2 Tourette syndrome cases of aripiprazole-related oculogyric crisis — sustained, involuntary upward eye deviation from extraocular-muscle dystonia — after titration to 20 mg and 30 mg daily, with remission after dose reduction.1 Research Highlights 2 new Tourette cases: Cavanna et al. reported oculogyric crisis in females aged 16 …
Social media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of severe mental disorders such as Schizophrenia and related psychotic disorders (SRD) and Bipolar Disorder (BD). Leveraging advanced artificial intelligence (AI) techniques, a comprehensive analysis of 893,289 tweets between 2008 and 2022 revealed significant …
Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …
It is estimated that 40% of U.S. adults are obese – and this figure is projected to continue growing. One potential reason for weight gain and a possible catalyst for obesity is use of pharmaceutical drugs (i.e. medications). Medication-induced weight gain poses a significant challenge in healthcare, affecting both patient well-being and treatment adherence. Key …
Abilify (Aripiprazole) is a medication that was developed by Otsuka Pharmaceuticals and approved by the FDA in 2002 for the treatment of schizophrenia. Approximately 2 years thereafter (in 2004) it was approved for the treatment of acute mania and mixed episodes associated with bipolar disorder. By 2007, it had attained approval for the treatment of …
Abilify (Aripiprazole) is an atypical antipsychotic drug that is commonly used to treat severe psychiatric conditions like schizophrenia and bipolar disorder. In recent years, it has been heavily marketed as an antidepressant augmentation strategy. Despite the fact that this has been one of the most profitable medications of recent years, some research has suggested that …